ABOUT US SCIENCE PIPELINE PATIENTS & CAREGIVERS INVESTORS/MEDIA INSIDE SIGILON Pioneering a novel approach to treating chronic disease with SHIELDED LIVING THERAPEUTICS™ LEARN MORE Look inside our technology Our Purpose Serious chronic diseases today are often treated with chronic therapies. For patients with diseases such as hemophilia, lysosomal diseases, or type 1 diabetes this amounts to less than ideal clinical outcomes combined with frequent injections and infusions — sometimes multiple times daily — and constant, lifelong vigilance to manage their disease. We developed our Shielded Living Therapeutics™ platform to address these treatment challenges. Leveraging advances in cell engineering and our proprietary biocompatible materials, we created a pipeline of potential therapies capable of producing molecules that may be missing or deficient in the body—potentially resulting in functional cures for patients with a wide range of chronic diseases. LEARN MORE Meet Our Team We’ve created an environment here where people are collaborative and friendly, and it makes it enjoyable coming to work every day. – Justin LEARN MORE Latest News and Events November 10, 2021 Sigilon Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights READ MORE November 9, 2021 Sigilon Therapeutics to Participate in the Jefferies London Healthcare Conference READ MORE ©2021 Sigilon Therapeutics, Inc. The marks SIGILON THERAPEUTICS, SIGILON, SHIELDED LIVING THERAPEUTICS, SLTX, AFIBROMER, AFIBROTEK, and our logos are trademarks of Sigilon Therapeutics, Inc. in the U.S. and other countries. All other marks are the property of their respective owners. Privacy Policy